MindMaze Advances European At-Home Rehab Strategy with Key Studies

  • MindMaze Therapeutics has enrolled first patients in SwissNeuroRehab HDHI neurorehabilitation study, targeting 300 minutes of active training per week across inpatient, outpatient, and home phases.
  • The CHF 11.2 million Innosuisse-backed SwissNeuroRehab consortium involves six major Swiss centers and aims to validate technology-supported neurorehabilitation pathways.
  • Parallel REACT-AVC study launched at Hospices Civils de Lyon focuses on early outpatient and home-based stroke rehabilitation in France.
  • MindMaze is leveraging these studies to establish reimbursement for at-home deployment across European markets, mirroring its U.S. strategy.

MindMaze is executing a coordinated strategy to establish at-home neurorehabilitation as a reimbursable standard in Europe, building on its successful U.S. model. The company's focus on generating clinical evidence through large-scale studies positions it to address the systemic shortage of specialized clinicians across multiple neurological conditions. This approach aligns with broader industry trends toward home-based care solutions and value-based healthcare delivery.

Reimbursement Momentum
Whether MindMaze can successfully replicate its U.S. reimbursement model in Europe through these clinical studies.
Study Outcomes
The pace at which SwissNeuroRehab and REACT-AVC generate compelling clinical and health-economic evidence for payers.
European Expansion
How quickly MindMaze can scale its at-home rehabilitation solutions across additional European markets beyond Switzerland and France.